Scilex (NASDAQ: SCLX)
Scilex Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Scilex Company Info
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
News & Analysis
Why Shares of Scilex Are Up Monday
An analyst at H.C. Wainwright initiated coverage on the stock.
Why Shares of Scilex Are Dropping Monday
The company's shares are being dragged down by its soon-to-be-former parent company.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.